Security Notice: Please be aware of impersonation attempts using our company name
Legitimate communications from Ascent Research will only come from official @ascentresearch.com email addresses.
Quick Order Cart

Cat. No. ARG43085

CCDC85C Knockout Hela Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Uterus (cervix)

  • Disease:

    Adenocarcinoma

CCDC85C Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population in which CCDC85C, a centriolar satellite component, has been disrupted. This HeLa-derived model enables loss-of-function studies of ciliogenesis and related signaling, as CCDC85C interacts with PCM1, CEP290, and CEP131 to regulate primary cilium assembly and Hedgehog pathway activity. The polyclonal format preserves genetic heterogeneity while abolishing target gene expression. The product is intended for investigating mechanisms of cilia biology, cancer cell behavior in a cervical adenocarcinoma background, and ciliopathy-associated pathways. Applications include immunofluorescence, western blotting, RT-qPCR, and functional assays, supporting drug screening and disease modeling efforts.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    HeLa

    Sex of Donor

    Female

    Age

    31 years

    Gene Name

    CCDC85C

    Gene Identifier

    NCBI Gene ID 317762

    Morphology

    Epithelial-like

    Growth Mode

    Adherent

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    MEM (with NEAA)

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The CCDC85C Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa human cervical adenocarcinoma cell line, engineered to disrupt the CCDC85C gene. This product provides a heterogeneous pool of cells with targeted gene disruption, creating a loss-of-function model that preserves genetic diversity while eliminating CCDC85C expression. The polyclonal format minimizes clonal selection biases and offers a reliable tool for studying CCDC85C function in centriolar satellite biology, ciliogenesis, and related signaling pathways.

HeLa cells are a widely utilized epithelial cell line originally isolated from a cervical adenocarcinoma, serving as a foundational model in cancer research, virology, and cell biology. Their robust growth characteristics and established genetic manipulation protocols make them an ideal host for generating knockout models. In this context, CCDC85C disruption in HeLa cells provides a unique platform to examine the role of centriolar satellites in cancer cell behavior and ciliary signaling.

CCDC85C is a core component of centriolar satellites, granular structures that cluster around the centrosome and regulate microtubule organization, cilia assembly, and protein trafficking. It interacts with key satellite proteins such as PCM1, CEP290, and CEP131, forming complexes that facilitate satellite biogenesis and ciliary vesicle transport. CCDC85C functions downstream of putative transcriptional regulators like RFX3 and FOXJ1, which are known to drive ciliogenic gene expression. Although its direct downstream targets remain undefined, CCDC85C likely influences ciliary membrane formation and Hedgehog pathway activation. Disruption of CCDC85C is expected to impair primary cilium assembly, thereby attenuating Hedgehog signaling??a pathway mediated by SMO and GLI transcription factors that governs cell fate and proliferation.

In the HeLa adenocarcinoma background, CCDC85C knockout holds particular significance for cancer biology. Primary cilia are frequently lost or disassembled in malignant cells, and their absence correlates with aberrant Hedgehog signaling and uncontrolled proliferation. By ablating CCDC85C, this model enables dissection of the relationship between centriolar satellite integrity, ciliogenesis, and oncogenic processes. Researchers can explore how ciliary dysfunction alters cell cycle progression, migration, and invasion in a well-characterized cervical cancer context, potentially uncovering novel therapeutic vulnerabilities.

This polyclonal knockout cell population is suitable for diverse experimental applications. It can be employed to investigate mechanisms of ciliogenesis using immunofluorescence microscopy to detect ciliary markers (e.g., acetylated ??-tubulin), or to assess signaling changes by RT-qPCR analysis of Hedgehog target genes (e.g., GLI1, PTCH1). Western blotting for ciliary components like ARL13B and IFT88 validates protein-level alterations, while flow cytometry enables cell cycle profiling. Altered migratory and invasive capacities can be examined via Transwell assays. The model also supports drug screening campaigns targeting cilia-dependent pathways or ciliopathies. For further information, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)